Methods for treating digitally identified IL-4/IL-13-related disorders by administering an anti-IL4R-alpha antibody
Disclosed are methods of treating various disorders with anti-IL-4Rα antibodies and fragments thereof.
1. A method of treating a subject with an anti-interleukin-4 receptor alpha (anti-IL-4Rα) antibody, comprising administering a therapeutically effective amount of an anti-IL-4Rα antibody to a subject exhibiting at least one symptom of a disorder selected from the group consisting of an esophageal-related disorder, a lung-related disorder, a blood-related disorder, a gastrointestinal-related disorder, a kidney-related disorder, a prostate-related disorder, Kawasaki's disease, a thyroid-related disorder, a blood-vessel-related disorder, a pregnancy-related disorder, and a cancer,
wherein the anti-IL-4Rα antibody comprises:
a variable heavy chain CDR1 of SEQ ID NO:1 (GFTFRDYA);
a variable heavy chain CDR2 of SEQ ID NO:2 (ISGSGGNT);
a variable heavy chain CDR3 of SEQ ID NO:3 (AKDRLSITIRPRYYGLDV);
a variable light chain CDR1 of SEQ ID NO:4 (QSLLYSIGYNY);
a variable light chain CDR2 of SEQ ID NO:5 (LGS); and
a variable light chain CDR3 of SEQ ID NO:6 (MQALQTPYT).
2. The method of claim 1 , wherein the anti-IL-4Rα antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO:13 and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO:14.
3. The method of claim 1 , wherein the subject is human.
4. The method of claim 1 , wherein the administering is selected from:
(a) intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, or epidural administration;
(b) via a pre-filled syringe;
(c) via a pre-filled pen; or
(d) via an autoinjector.
5. The method of claim 1 , wherein the anti-IL-4Rα antibody is administered over multiple doses.
6. The method of claim 1 , wherein the anti-IL-4Rα antibody is administered at a dose of about 0.0001 to about 10 mg/kg of patient body weight.
7. The method of claim 1 , further comprising administering a second therapeutic agent selected from a second antibody or antigen binding fragment thereof, a soluble cytokine receptor, an IgE antagonist, or an anti-asthma medication,
wherein the anti-asthma medication is a corticosteroid, a non-steroidal agent, a beta agonist, a leukotriene antagonist, a xanthine, fluticasone, salmeterol, or albuterol.
8. The method of claim 1 , wherein the lung-related disorder is lung fibrosis.
9. The method of claim 1 , wherein the lung-related disorder is lung cirrhosis.
10. The method of claim 1 , wherein the lung-related disorder is chronic fibrotic lung disease.
11. The method of claim 1 , wherein the lung-related disorder is cystic fibrosis.
12. The method of claim 1 , wherein the lung-related disorder is bleomycin-induced pneumopathy and fibrosis.
13. The method of claim 1 , wherein the lung-related disorder is pulmonary alveolar proteinosis.
14. The method of claim 1 , wherein the lung-related disorder is adult respiratory distress syndrome.
15. The method of claim 1 , wherein the lung-related disorder is sarcoidosis.
16. The method of claim 1 , wherein the lung-related disorder is tuberculosis.
17. The method of claim 1 , wherein the lung-related disorder is aspirin-exacerbated respiratory disease.
18. The method of claim 1 , wherein the blood-related disorder is sickle cell disease.
19. The method of claim 1 , wherein the blood-related disorder is Churg-Strauss syndrome.
20. The method of claim 1 , wherein the blood-related disorder is autoimmune lymphoproliferative syndrome.
21. The method of claim 1 , wherein the blood-related disorder is systemic lupus erythematosus.
22. The method of claim 1 , wherein the blood-related disorder is antiphospholipid antibody syndrome (APS).
23. The method of claim 1 , wherein the blood-related disorder is autoimmune hemolytic anemia.
24. The method of claim 1 , wherein the esophageal-related disorder is Barrett's esophagus.
25. The method of claim 1 , wherein the esophageal-related disorder is eosinophilic gastritis.
26. The method of claim 1 , wherein the esophageal-related disorder is achalasia.
27. The method of claim 1 , wherein the esophageal-related disorder is gastroesophageal reflux disease (GERD).
28. The method of claim 1 , wherein the gastrointestinal-related disorder is ulcerative colitis.
29. The method of claim 1 , wherein the gastrointestinal-related disorder is Whipple's disease.
30. The method of claim 1 , wherein the gastrointestinal-related disorder is Behçet's disease.
31. The method of claim 1 , wherein the gastrointestinal-related disorder is Wegener granulomatosis.
32. The method of claim 1 , wherein the kidney-related disorder is nephrosis.
33. The method of claim 1 , wherein the kidney-related disorder is glomerulonephritis.
34. The method of claim 1 , wherein the kidney-related disorder is Goodpasture syndrome.
35. The method of claim 1 , wherein the prostate-related disorder is benign prostrate hyperplasia.
36. The method of claim 1 , wherein the prostate-related disorder is chronic prostatitis syndrome.
37. The method of claim 1 , wherein the disorder is Kawasaki's disease.
38. The method of claim 1 , wherein the pregnancy-related disorder is pre-eclampsia.
39. The method of claim 1 , wherein the pregnancy-related disorder is antiphospholipid syndrome.
40. The method of claim 1 , wherein the pregnancy-related disorder is immune thrombocytopenia.
41. The method of claim 1 , wherein the cancer is a cutaneous T-cell lymphoma.
42. The method of claim 1 , wherein the administering is via a pre-filled syringe.
43. The method of claim 1 , wherein the administering is via a pre-filled pen.
44. The method of claim 1 , wherein the administering is via an autoinjector.
45. The method of claim 1 , wherein the anti-IL-4Rα antibody is administered to the subject as an initial dose followed by one or more secondary doses.
46. The method of claim 45 , wherein the initial dose is about 600 mg and each secondary dose is about 300 mg.
47. The method of claim 45 , wherein the initial dose is about 400 mg and each secondary dose is about 200 mg.
48. The method of claim 45 , wherein each secondary dose is administered every 2 weeks.